| ²é¿´: 6142 | »Ø¸´: 8 | ||||
[½»Á÷]
¡¾ÇóÖú¡¿Ò©ÎïÁÙ´²IaÆÚÊÇʲôÒâ˼?ÇóÏê½â
|
| ÁÙ´²ÊÔÑéÖеÄIa£¬Ib£¬Ic±íʾʲôÒâË¼ÄØ£¿ÊDz»ÊÇÿÆÚÁÙ´²¶¼ÓÐÕâÑùµÄ»®·ÖÂ𣿠|
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
Ò©ÎïÁÙ´²ÊÔÑ龫»ªÌû |
» ²ÂÄãϲ»¶
ÖÆÒ©¹¤³ÌרҵÕÐÊÕµ÷¼Á£¬ÒªÇó¹ý¹ú¼ÒÏß
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ66È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
AcsÔÓÖ¾JAFCͶ¸åÇóÖú
ÒѾÓÐ4È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Çó¸ßÊÖ°ïæ½âÎöÒ»¸ö¾§Ìå½á¹¹ ÔÚÏßµÈ
ÒѾÓÐ5È˻ظ´
mp-zgm£º£¨+£©ÊÇʲôÒâ˼
ÒѾÓÐ7È˻ظ´
ÇóÖú£¡ÇëÎÊÕâÊÇʲôÒâ˼£¿
ÒѾÓÐ7È˻ظ´
Í¿ÁÏÖÐÓë·ÖÉ¢¼ÁÓÃÁ¿Ïà¹ØµÄÑÕÁÏSOPÊÇʲôÒâ˼£¿ÊÇʲôµÄËõд£¿ÇóÏê½â¡£
ÒѾÓÐ7È˻ظ´
Ͷ¸åÁ½Ì죬±à¼À´ÐÅÒªÇ󣬵ÚÒ»¸öÒªÇóûÔõô¿´¶®¡£Çë½ÌÕâÊÇʲôÒâ˼£¿
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿Íâµ¼ÒÑ·¢ÑûÇëÐÅ£¬ÕýÔÚ̸ѧϰ¼Æ»®¡£Âé·³´ó¼Ò°ïÎÒ¿´Ò»ÏÂÕâ¾ä»°ÊÇʲôÒâ˼¡£
ÒѾÓÐ13È˻ظ´
¡¾ÇóÖú¡¿ÎÄÏ×ÖеÄIa3dºÍp6mm·Ö±ðÊÇʲôÒâ˼£¿
ÒѾÓÐ3È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Öйú¿ÆÑ§Ôº¹ý³Ì¹¤³ÌÑо¿Ëù ÄÜÔ´»·¾³¿ÎÌâ×é ²©Ê¿ºóÕÐÆ¸Æôʾ
+1/183
2026 ˶ʿÑо¿Éúµ÷¼Á£üºÓÄϹ¤Òµ´óѧ»¯Ñ§»¯¹¤Ñ§ÔºÃû¶î¿ª·Å
+2/58
ÈýÏ¿´óѧ²Ä»¯Ñ§Ôº»¯¹¤Ð²ÄÁÏ¿ÎÌâ×éÏÖÕÐÊÕ»¯Ñ§»òÕß»¯¹¤¡¢²ÄÁÏ˶ʿÑо¿Éú2Ãû
+5/55
ɽ¶«Çൺ-µ¼Ê¦ÕÐÉú
+1/51
ÕÐÊÕ2026¼¶¹«¹²ÎÀÉúÓëÔ¤·Àҽѧרҵ£¨Ñ§Ë¶£©µ÷¼ÁÉú1Ãû
+1/46
ÑĮ̀´óѧ»·¾³Óë²ÄÁϹ¤³ÌѧԺ2026Äê˶ʿÑо¿ÉúÕÐÉú
+1/45
Ìì½ò¿Æ´óÇṤѧԺ¹ú¼Ò¼¶È˲ÅÍŶÓÕÐÊÕ»¯Ñ§¡¢²ÄÁÏ¡¢Ê³Æ·µ÷¼Á
+1/38
ÎåÒØ´óѧÂí°®¾ü¿ÎÌâ×éÕÐÊÕҩѧ¡¢ÉúÎïÓëÒ½Ò©µ÷¼ÁÉú
+1/37
¿¼Ñе÷¼ÁÕÐÉú
+1/24
¹ãÖÝÒ½¿Æ´óѧÉúÎïҽѧ¹¤³ÌÉúÎï¼¼ÊõÓ빤³Ì£¨086001£©ºÍÖÆÒ©¹¤³Ì£¨086002£©½ÓÊÕµ÷¼Á
+1/9
Î÷±±¹¤Òµ´óѧ»úµçѧԺ ¸´ºÏ²ÄÁϼӹ¤ÖÆÔì·½ÏòÕÐÆ¸²©Ê¿ºó
+1/8
ÈýÏ¿´óѧ ÕÐÊÕµ÷¼Á£¨Êýѧ¡¢ÎïÀíѧ¡¢Á¦Ñ§¡¢¹¤Ñ§£©
+1/7
ÖйúÁÖ¿ÆÔºÄ¾²ÄËù˶ʿµ÷¼Á
+1/6
¡¾µ÷¼ÁÉϰ¶¡¿985ÁªºÏÅàÑø£¡1007/1055/08/07µÈ£¬²»ÏÞרҵ£¬ÏëÁªÅàµÄËÙÀ´£¡
+1/6
ËÕÖݿƼ¼´óѧºúÀÏʦ¿ÎÌâ×éÕÐ2026Äê˶ʿÉúÈô¸ÉÃû
+1/5
¡¾ÉϺ£µ÷¼Á¡¿985ÁªºÏÅàÑø£¡±ð´í¹ýÄÜËÍÄãÈ¥µ¤Âó/½»´ó/ͬ¼Ã/ÖпÆÔºµÄÉñÏɵ¼Ê¦£¡
+1/5
²»´ò¿¨-µ¯ÐÔ¹¤×÷ÖÆ¿ÎÌâ×éÕÐÉú
+1/5
µ÷¼ÁÕÐÉú»¯Ñ§»¯¹¤£¨0817¡¢0856£©
+1/3
ÉϺ£Ó¦Óü¼Êõ´óѧ»¯¹¤ÔºÕÐÊÕµ÷¼Á
+1/2
Î÷°²¹¤³Ì´óѧ»·¾³Ó뻯ѧ¹¤³ÌѧԺÀÏʦÕÐÓлúѧÉúµ÷¼Á~
+1/2
¡ï
warlen(½ð±Ò+1):лл²ÎÓë 2010-12-02 09:17:05
smy05106111(½ð±Ò+2): 2010-12-08 15:48:35
warlen(½ð±Ò+1):лл²ÎÓë 2010-12-02 09:17:05
smy05106111(½ð±Ò+2): 2010-12-08 15:48:35
| IÆÚÁÙ´²ÊÔÑé·½°¸Ó¦°üÀ¨ÒÀ´Î½øÐеÄÈý²¿·Ö£¬¼´µ¥´Î¸øÒ©ÄÍÊÜÐÔÊÔÑé·½°¸¡¢µ¥´Î¸øÒ©Ò©´ú¶¯Á¦Ñ§ÊÔÑé·½°¸¡¢Á¬Ðø¸øÒ©Ò©´ú¶¯Á¦Ñ§ÊÔÑé·½°¸¡£ |
2Â¥2010-12-02 09:08:32
3Â¥2010-12-02 20:21:52
ѼÂ̽ÅÏ
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 839 (²©ºó)
- ¹ó±ö: 0.384
- ½ð±Ò: 12365.3
- Ìû×Ó: 1723
- ÔÚÏß: 656.6Сʱ
- ³æºÅ: 294537
smy05106111(½ð±Ò+3): 2010-12-08 15:48:43
|
Phase II Once the initial safety of the study drug has been confirmed in Phase I trials, Phase II trials are performed on larger groups (20-300) and are designed to assess how well the drug works, as well as to continue Phase I safety assessments in a larger group of volunteers and patients. When the development process for a new drug fails, this usually occurs during Phase II trials when the drug is discovered not to work as planned, or to have toxic effects. Phase II studies are sometimes divided into Phase IIA and Phase IIB. * Phase IIA is specifically designed to assess dosing requirements (how much drug should be given). * Phase IIB is specifically designed to study efficacy (how well the drug works at the prescribed dose(s)). Some trials combine Phase I and Phase II, and test both efficacy and toxicity. Trial design Some Phase II trials are designed as case series, demonstrating a drug's safety and activity in a selected group of patients. Other Phase II trials are designed as randomized clinical trials, where some patients receive the drug/device and others receive placebo/standard treatment. Randomized Phase II trials have far fewer patients than randomized Phase III trials. |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
4Â¥2010-12-08 13:58:30
5Â¥2010-12-08 15:49:28
¡ï ¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
warlen(½ð±Ò+2):лл²ÎÓë 2010-12-13 16:28:38
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
warlen(½ð±Ò+2):лл²ÎÓë 2010-12-13 16:28:38
|
·Òë³ÉÁËÖÐÎİ棬Äã¿ÉÒÔ½è¼øÒ»Ï£¬²»Ò»¶¨×¼È·£¬²Î¿¼°É¡£ ¶þÆÚÁÙ´² Ò»µ©Ñо¿Ò©ÎïµÄ³õÆÚ°²È«ÐÔÔÚµÚÒ»½×¶Î±»Ö¤ÊµÁË£¬¶þÆÚÁÙ´²ÐèÒª¶Ô¸ü´óµÄÊýÁ¿£¨20-300£©½øÐÐÑéÖ¤£¬ÆÀ¹ÀÒ©ÎïÈçºÎ·¢»Ó×÷Ó㬸ü¶àµÄÖ¾Ô¸ÕߺͲ¡È˲ÎÓëÒÔ½øÒ»²½ÆÀ¹ÀÒ»ÆÚÁÙ´²µÄ°²È«ÐÔ¡£Ò»ÖÖÐÂÒ©µÄÑз¢¹ý³Ìʧ°ÜÍùÍù·¢ÉúÔÚ¶þÆÚÁÙ´²£¬´Ëʱ·¢ÏÖÒ©ÎïûÓа´Õռƻ®Æð×÷Ó㬻òÕß¾ßÓж¾ÐÔ¡£ ¶þÆÚÁÙ´²Ñо¿Í¨³£·ÖΪaºÍbÁ½¸ö½×¶Î aÓÃÓÚÆÀ¹À¼ÁÁ¿ÒªÇó£¨Ó¦¸ÃÓÃÒ©¶àÉÙ£© bÓÃÓÚÆÀ¹ÀҩЧ£¨Ìض¨¼ÁÁ¿Ê±Ò©ÎïÈçºÎ·¢»Ó×÷Óã© һЩÊÔÑéÓÐÒ»ÆÚºÍ¶þÆÚ×é³É£¬¼ìÑéÓÐЧÐԺͶ¾ÐÔ ÊÔÑéÉè¼Æ£º ²¿·Ö¶þÆÚÁÙ´²µÄÄ¿µÄÊÇÖ¤Ã÷Ò©ÎïµÄ°²È«ÐԺͶÔÑ¡¶¨µÄ²¡È˵ĻîÐÔ¡£ÆäËûµÄÊÇËæ»úÁÙ´²ÊÔÑ飬һ²¿·Ö²¡È˽ÓÊÜÒ©Îï/Ò½ÁÆÆ÷еºÍÁíÒ»²¿·Ö¶ÔÕÕÆ·/±ê׼ƷÖÎÁÆ¡£Ëæ»ú¶þÆÚÁÙ´²ÊÔÑé±ÈËæ»úÈýÆÚÁÙ´²²¡ÈËÉٺܶࡣ |
6Â¥2010-12-13 14:02:04
¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
warlen(½ð±Ò+1):лл²ÎÓë 2010-12-13 16:28:49
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
warlen(½ð±Ò+1):лл²ÎÓë 2010-12-13 16:28:49
| ÿһÆÚÁÙ´²ÊÔÑéÖеÄa,b,c,ÊÇ´ú±í²»Í¬·½°¸£¬Ï൱ÓÚ1,2,3£¬Ö»ÊDZí´ï·½Ê½²»Ò»Ñù¶øÒÑ¡£±ÈÈç˵£ºIÆÚÁÙ´²ÊÔÑ鲻д³ÉÒ»ÆÚÁÙ´²ÊÔÑé¡£ |
7Â¥2010-12-13 14:39:20
8Â¥2011-09-29 18:30:37
9Â¥2019-03-04 10:56:50














»Ø¸´´ËÂ¥

wx825061